Alligator Bioscience Logo

Alligator Bioscience

ISIN: SE0000767188 | Ticker: ATORX | LEI: 549300E15VI0MB7LXV19
Sector: Health CareSub-Industry: Biotechnology
Country: Sweden

About Alligator Bioscience

Company Description

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase 2 studies and beyond.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Year founded

2001

Served area

Worldwide

Headquarters

Scheelevägen 2, 22381 Lund – Sweden

Financial statements

Download as Excel
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 151,938,000.00 333,200,000.00 169,584,000.00
Noncurrent Assets N/A 41,593,000.00 33,587,000.00 46,770,000.00
Other Property Plant And Equipment N/A 8,600,000.00 4,355,000.00 1,386,000.00
Computer Software N/A 332,000.00 201,000.00 70,000.00
Other Noncurrent Receivables N/A N/A 0.00 1,815,000.00
Current Assets N/A 110,345,000.00 299,613,000.00 122,814,000.00
Current Trade Receivables N/A 0.00 7,446,000.00 13,930,000.00
Other Current Receivables N/A 4,924,000.00 7,044,000.00 3,636,000.00
Cash and cash equivalents 93,890,000.00 103,342,000.00 278,148,000.00 97,305,000.00
Equity And Liabilities N/A 151,938,000.00 333,200,000.00 169,584,000.00
Equity 258,498,000.00 115,244,000.00 282,273,000.00 89,051,000.00
Issued Capital N/A 28,555,000.00 88,234,000.00 88,614,000.00
Retained Earnings N/A -576,052,000.00 -717,792,000.00 -911,463,000.00
Additional Paidin Capital N/A 662,741,000.00 911,831,000.00 911,901,000.00
Equity Attributable To Owners Of Parent N/A 115,244,000.00 282,273,000.00 89,051,000.00
Noncurrent Liabilities N/A 5,975,000.00 3,511,000.00 16,003,000.00
Other Noncurrent Liabilities N/A 135,000.00 0.00 N/A
Current Liabilities N/A 30,719,000.00 47,416,000.00 64,529,000.00
Trade And Other Current Payables To Trade Suppliers N/A 6,538,000.00 9,367,000.00 13,343,000.00
Current Accruals And Current Deferred Income Including Current Contract Liabilities N/A N/A 29,586,000.00 39,655,000.00
Other Current Liabilities N/A 1,879,000.00 2,237,000.00 3,032,000.00
Line item in (sek) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue From Contracts With Customers 4,352,000.00 12,943,000.00 35,696,000.00
Other Income 2,315,000.00 2,183,000.00 1,439,000.00
Employee Benefits Expense 55,710,000.00 57,814,000.00 68,836,000.00
Depreciation And Amortisation Expense 11,522,000.00 11,144,000.00 11,767,000.00
Other Expense By Nature 1,413,000.00 751,000.00 1,597,000.00
Profit Loss From Operating Activities -144,298,000.00 -141,565,000.00 -192,789,000.00
Finance Income 2,001,000.00 -2,000.00 32,000.00
Finance Costs 1,191,000.00 169,000.00 646,000.00
Profit Loss Before Tax -143,296,000.00 -141,736,000.00 -193,403,000.00
Income Tax Expense Continuing Operations 0.00 0.00 0.00
Profit (loss) -143,296,000.00 -141,736,000.00 -193,403,000.00
Profit Loss Attributable To Owners Of Parent -143,296,000.00 -141,736,000.00 -193,403,000.00
Line item in (sek) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A -143,296,000.00 -141,736,000.00 -193,403,000.00
Adjustments For Depreciation And Amortisation Expense N/A 11,522,000.00 11,144,000.00 11,767,000.00
Adjustments For Sharebased Payments N/A 42,000.00 4,000.00 99,000.00
Other Adjustments For Noncash Items N/A 0.00 65,000.00 -19,000.00
Interest Paid Classified As Operating Activities N/A 347,000.00 235,000.00 646,000.00
Interest Received Classified As Operating Activities N/A 218,000.00 0.00 N/A
Cash Flows From Used In Operating Activities N/A -141,352,000.00 -127,033,000.00 -172,607,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 102,000.00 45,000.00 440,000.00
Cash Flows From Used In Investing Activities N/A 156,886,000.00 -45,000.00 -440,000.00
Proceeds From Issuing Shares N/A 0.00 342,665,000.00 380,000.00
Payments To Acquire Or Redeem Entitys Shares N/A N/A 0.00 380,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 354,000.00 301,000.00 104,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 5,794,000.00 6,672,000.00 7,806,000.00
Cash Flows From Used In Financing Activities N/A -6,148,000.00 301,795,000.00 -7,827,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 145,000.00 60,000.00 32,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A 9,386,000.00 174,717,000.00 -180,875,000.00
Cash and cash equivalents 93,890,000.00 103,342,000.00 278,148,000.00 97,305,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Date Trading entity / Person Association Trade type Volume
11.04.24 Staffan Encrantz Other Sell SEK 47,196,181.67
27.10.22 Sören Bregenholt Frederiksen Other Buy SEK 72,748.00
25.10.22 Marie Svensson Other Buy SEK 16,632.00
19.08.22 Sören Bregenholt Frederiksen Other Buy SEK 25,726.10
18.08.22 Sören Bregenholt Frederiksen Other Buy SEK 56,911.35
31.05.22 Peter Ostler Other Buy SEK 151,500.00
04.05.22 Sören Bregenholt Frederiksen Other Buy SEK 50,895.00
02.05.22 Sören Bregenholt Frederiksen Other Buy SEK 50,811.00
30.04.22 Sören Bregenholt Frederiksen Other Buy SEK 51,171.00
26.11.21 Anders Ekblom Other Buy SEK 111,806.00

Capital markets information

ISIN

SE0000767188

LEI

549300E15VI0MB7LXV19

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.